Viking Therapeutics Inc. (NASDAQ:VKTX) saw an upside of 11.88% to close Tuesday at $14.22 after adding $1.51 on the day. The 5-day average trading volume is 2,229,040 shares of the company’s common stock. It has gained $14.36 in the past week and touched a new high 2 times within the past 5 days. An average of 1,814,925 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,669,306.
VKTX’s 1-month performance is -11.01% or -$1.16 on its low of $12.62 reached on 08/07/23. The company’s shares have touched a 52-week low of $2.53 and high of $25.72, with the stock’s rally to the 52-week high happening on 05/23/23. YTD, VKTX has achieved 51.28% or $4.82 and has reached a new high 29 times. However, the current price is down -44.71% from the 52-week high price.
Insider Transactions
VKTX stock investors last saw insider trading activity on May 16.Rowland Charles A Jr (Director) most recently sold 40,000 shares at $25.00 per share on May 16. This transaction cost the insider $1,000,000. Director, MACARTNEY LAWSON, sold 16,000 shares at a price of $24.00 on May 16. Then, on May 01, President & CEO Lian Brian sold 45,000 shares at a price of $22.45 per share. This transaction amounted to $1,010,250.
Valuation Metrics
VKTX stock has a beta of 0.53. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 3.65.
Viking Therapeutics Inc.’s quick ratio for the period ended June 29 was 29.60, with the current ratio over the same period at 29.60.
Earnings Surprise
For the quarterly period ending June 29 this year, Viking Therapeutics Inc.’s cash and short-term investments amounted to $323.4 million against total debt of $1.41 million. Net income grew 9.36% to -$19.23 million, while revenue of -$19.53 million was -1.56% off the previous quarter. Analysts expected VKTX to announce -$0.19 per share in earnings in its latest quarter, but it posted -$0.19, representing a 0.00% surprise. VKTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 14.58 million, with total debt at $1.41 million. Shareholders hold equity totaling $100.03 million.
Let’s look briefly at Viking Therapeutics Inc. (VKTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 47.64% to suggest the stock is trending Neutral, with historical volatility in this time period at 75.88%.
The stock’s 5-day moving average is $13.49, reflecting a +0.42% or $0.06 change from its current price. VKTX is currently trading -11.12% above its 20-day SMA, +33.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -31.96% and SMA200 by+300.56%.
Stochastic %K and %D was 22.62% and 15.92% and the average true range (ATR) pointed at 0.88. The RSI (14) points at 42.22%, while the 14-day stochastic is at 53.16% with the period’s ATR at 0.92. The stock’s 9-day MACD Oscillator is pointing at -0.46 and -0.81 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for VKTX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate VKTX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 10 have offered a “buy” rating.
What is VKTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $28.00 and a high of $40.00, with their median price target at $34.00. Looking at these predictions, the average price target given by analysts is for Viking Therapeutics Inc. (VKTX) stock is $33.80.
